New Medication Aimed to Slow the Progression of Alzheimer’s disease

This 78 week study is assessing the safety and efficacy of the medication Bapineuzumab in treating patients with mild to moderate Alzheimer’s disease.

Major Inclusion/Exclusion

  • Ages 50- 89 yrs.
  • MMSE 16-26 inclusive
  • Auto-immune disease is excluded
  • History of stroke is excluded